C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke.
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
19
07
2019
revised:
19
12
2019
accepted:
20
12
2019
pubmed:
25
1
2020
medline:
22
6
2021
entrez:
25
1
2020
Statut:
ppublish
Résumé
Intravenous thrombolysis (IVT) after stroke enhances C3a generation, which may abrogate the benefits of reperfusion. The C3aR antagonist SB290157 is neuroprotective following transient but not permanent middle cerebral artery occlusion (MCAo). SB290157 remains untested in thromboembolic (TE) models, which better approximate human stroke and also facilitate testing in combination with IVT. We hypothesized SB290157 would confer neuroprotection in TE stroke with and without "late" IVT. We used two different models of TE stroke to examine the efficacy of SB290157 alone and in combination with late IVT. We evaluated the benefit of SB290157 in attenuating post-ischaemic behavioural deficits, infarction, brain oedema and haemorrhage. Plasma C3a was elevated 6 hr after TE stroke alongside increased cerebrovascular C3aR expression, which was sustained to 4 weeks. Increased C3aR expression also was visualized in human ischaemic brain. In a photothrombotic (PT) stroke model, which exhibits rapid spontaneous reperfusion, SB290157 given at 1 hr post-PT significantly improved neurofunction and reduced infarction at 48 hr. In an embolic (eMCAo) model, SB290157 administered at 2 hr improved histological and functional outcomes. Conversely, late IVT administered 4.5 hr post-eMCAo was ineffective likely due to increased haemorrhage and brain oedema. However, SB290157 administered prior to late IVT ameliorated haemorrhage and oedema and improved outcomes. We conclude that SB290157 is safe and effective with and without late IVT following TE stroke. Therefore, C3a receptor antagonist therapy represents a promising candidate for clinical translation in stroke, particularly as an adjuvant to IVT.
Sections du résumé
BACKGROUND AND PURPOSE
Intravenous thrombolysis (IVT) after stroke enhances C3a generation, which may abrogate the benefits of reperfusion. The C3aR antagonist SB290157 is neuroprotective following transient but not permanent middle cerebral artery occlusion (MCAo). SB290157 remains untested in thromboembolic (TE) models, which better approximate human stroke and also facilitate testing in combination with IVT. We hypothesized SB290157 would confer neuroprotection in TE stroke with and without "late" IVT.
EXPERIMENTAL APPROACH
We used two different models of TE stroke to examine the efficacy of SB290157 alone and in combination with late IVT. We evaluated the benefit of SB290157 in attenuating post-ischaemic behavioural deficits, infarction, brain oedema and haemorrhage.
KEY RESULTS
Plasma C3a was elevated 6 hr after TE stroke alongside increased cerebrovascular C3aR expression, which was sustained to 4 weeks. Increased C3aR expression also was visualized in human ischaemic brain. In a photothrombotic (PT) stroke model, which exhibits rapid spontaneous reperfusion, SB290157 given at 1 hr post-PT significantly improved neurofunction and reduced infarction at 48 hr. In an embolic (eMCAo) model, SB290157 administered at 2 hr improved histological and functional outcomes. Conversely, late IVT administered 4.5 hr post-eMCAo was ineffective likely due to increased haemorrhage and brain oedema. However, SB290157 administered prior to late IVT ameliorated haemorrhage and oedema and improved outcomes.
CONCLUSIONS AND IMPLICATIONS
We conclude that SB290157 is safe and effective with and without late IVT following TE stroke. Therefore, C3a receptor antagonist therapy represents a promising candidate for clinical translation in stroke, particularly as an adjuvant to IVT.
Identifiants
pubmed: 31975437
doi: 10.1111/bph.14989
pmc: PMC7205805
doi:
Substances chimiques
Fibrinolytic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2466-2477Subventions
Organisme : Barrow Neurological Foundation
Pays : International
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The British Pharmacological Society.
Références
J Cereb Blood Flow Metab. 2008 May;28(5):1048-58
pubmed: 18197178
Nat Rev Immunol. 2009 Oct;9(10):729-40
pubmed: 19730437
Br J Pharmacol. 2019 Dec;176 Suppl 1:S297-S396
pubmed: 31710714
Brain. 2017 Feb;140(2):353-369
pubmed: 27956400
Transl Stroke Res. 2018 Oct;9(5):530-539
pubmed: 29285679
Neuron. 2018 Dec 19;100(6):1337-1353.e5
pubmed: 30415998
Circulation. 2013 Jan 1;127(1):e6-e245
pubmed: 23239837
J Neurosci Methods. 2002 Jun 30;117(2):207-14
pubmed: 12100987
Br J Pharmacol. 2020 Jun;177(11):2466-2477
pubmed: 31975437
Immunol Lett. 2005 Sep 15;100(2):139-45
pubmed: 16154494
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
J Immunol. 2005 Jun 15;174(12):7479; author reply 7479-80
pubmed: 15944244
Acta Ophthalmol. 2012 Dec;90(8):695-703
pubmed: 22067048
Stroke. 2009 Jul;40(7):2594-600
pubmed: 19478212
PLoS One. 2017 Jul 10;12(7):e0180822
pubmed: 28700732
Transl Stroke Res. 2016 Aug;7(4):261-73
pubmed: 26830778
Transl Stroke Res. 2018 Feb;9(1):51-63
pubmed: 28755277
J Neurosci Methods. 2015 Dec 30;256:203-11
pubmed: 26386284
Br J Pharmacol. 2019 Dec;176 Suppl 1:S397-S493
pubmed: 31710713
J Cereb Blood Flow Metab. 2017 Jul;37(7):2539-2554
pubmed: 27683449
PLoS One. 2013 Aug 20;8(8):e72133
pubmed: 23977229
Immunobiology. 2012 Nov;217(11):1026-33
pubmed: 22964228
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
J Cereb Blood Flow Metab. 2019 Aug;39(8):1635-1647
pubmed: 29537907
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Endocr Metab Immune Disord Drug Targets. 2012 Jun;12(2):148-58
pubmed: 22236022
J Neuroinflammation. 2017 Dec 15;14(1):248
pubmed: 29246244
Stroke. 2018 Sep;49(9):2241-2247
pubmed: 30355006
Transl Stroke Res. 2014 Aug;5(4):484-90
pubmed: 24385308
J Cereb Blood Flow Metab. 2007 Mar;27(3):435-51
pubmed: 16804552
J Immunol. 2001 May 15;166(10):6341-8
pubmed: 11342658
Neurochem Int. 2019 Jul;127:22-28
pubmed: 30654116
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
J Neuroinflammation. 2016 Jan 28;13:23
pubmed: 26822321
Br J Pharmacol. 2015 May;172(10):2427-32
pubmed: 25899710
Stroke. 2012 Oct;43(10):2794-9
pubmed: 22910893
Exp Neurol. 2009 Oct;219(2):398-403
pubmed: 19632224
Cerebrovasc Dis. 2011;32(2):114-22
pubmed: 21709409
Interv Neurol. 2013 Sep;1(3-4):185-99
pubmed: 25187778
J Cereb Blood Flow Metab. 2013 Mar;33(3):330-8
pubmed: 23232947
Circ Res. 2006 Jul 21;99(2):209-17
pubmed: 16778128
Br J Pharmacol. 2018 Feb;175(3):407-411
pubmed: 29350411
J Cereb Blood Flow Metab. 2009 Jan;29(1):98-107
pubmed: 18728680
Exp Neurobiol. 2019 Apr;28(2):216-228
pubmed: 31138990
Transl Stroke Res. 2013 Aug;4(4):381-9
pubmed: 23853671
FASEB J. 2016 Jun;30(6):2336-50
pubmed: 26956419
PLoS One. 2012;7(6):e38664
pubmed: 22761695
J Surg Res. 2011 Oct;170(2):e263-70
pubmed: 21816416
Stroke. 1997 Nov;28(11):2296-302
pubmed: 9368579
Steroids. 2007 May;72(5):381-405
pubmed: 17379265
Stroke. 2017 Jun;48(6):1695-1699
pubmed: 28428349